WaveMan
WaveMan · Company
HYPD · Hyperion Defi, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

HYPD Hyperion Defi (HYPD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001682639
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter

What the filings say about HYPD

Insiders, 180 days
+$29.6K net bought
1 buyer

Hyperion Defi insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, HYPERION DEFI, INC. insiders bought a net $29.6K of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Jung Hyunsu
See Remarks
BUY
2026-06-02 SEC
500
$1.8K
-21.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 1, 2026.
  • The trade is 0.0% of the 1,385,176 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jung Hyunsu bought about $1.8K of HYPD on Jun 2, 2026; 19 funds added in the latest 13F quarter.
Jung Hyunsu
See Remarks
BUY
2026-06-02 SEC
500
$1.8K
-21.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 1, 2026.
  • The trade is 0.0% of the 1,385,676 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jung Hyunsu bought about $1.8K of HYPD on Jun 2, 2026; 19 funds added in the latest 13F quarter.
Jung Hyunsu
See Remarks
BUY
2026-06-02 SECtraded 2026-06-01
5,000
$18.3K
-21.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.4% of the 1,382,676 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jung Hyunsu bought about $18.3K of HYPD on Jun 1, 2026; 19 funds added in the latest 13F quarter.
Jung Hyunsu
See Remarks
BUY
2026-06-02 SECtraded 2026-06-01
2,000
$7.6K
-21.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.1% of the 1,384,676 shares held after it.
  • No other insider bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Jung Hyunsu bought about $7.6K of HYPD on Jun 1, 2026; 19 funds added in the latest 13F quarter.
Knox David R.
Chief Financial Officer
BUY
2026-01-05 SECtraded 2025-12-31
27,950
$100.3K
-26.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 8.5% of the 327,950 shares held after it.
  • 3 other insiders bought within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Knox David R. bought about $100.3K of HYPD on Dec 31, 2025; 3 other insiders bought within 30 days and 19 funds added in the latest 13F quarter.
13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 8 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$29.6K over 180 days
more than 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
+1318.8% year over year
more than 97% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
9.4% of the float short (float per yahoo 2026-10-27) · 3.7 days to cover · settled 2026-10-15
more than 66% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch HYPD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-64.7%12M
-71%-46%-21%+3%2025-102025-122026-022026-042026-062026-082026-10 2025-12-17 · Walters Happy David bought $187.0K2025-12-31 · Knox David R. bought $100.3K2025-12-17 · GELTZEILER MICHAEL S bought $90.3K2025-12-18 · Strahlman Ellen R bought $61.9K2025-12-18 · Strahlman Ellen R bought $58.8K2025-12-29 · Strahlman Ellen R bought $43.6K2025-12-29 · Strahlman Ellen R bought $42.8K2026-06-01 · Jung Hyunsu bought $18.3K2025-12-26 · Strahlman Ellen R bought $13.9K2025-12-26 · Strahlman Ellen R bought $12.8K2026-06-01 · Jung Hyunsu bought $7.6K2026-06-02 · Jung Hyunsu bought $1.8K2026-06-02 · Jung Hyunsu bought $1.8K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns HYPD: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
466,798 sh
$1.5M
FRANKLIN RESOURCES INC
395,939 sh
$1.2M
Arrington Capital Management, LLC
297,777 sh
$935.0K
MORGAN STANLEY
237,986 sh
$747.3K
Almanack Investment Partners, LLC.
169,013 sh
$530.7K

Congress trades in HYPD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

HYPD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

HYPD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Putnam Small Cap Value Fund
$1.0M position · as of 2026-05-31
0.3%
Putnam VT Small Cap Value Fund
$342.8K position · as of 2026-06-30
0.3%
iShares Micro-Cap ETF
$106.8K position · as of 2026-06-30
0.0%
T. Rowe Price Extended Equity Market Index Fund
$64.4K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$7.2K position · as of 2026-06-30
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$552.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $29.6K bought by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

HYPD financials

Revenue growth
+1318.8%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+474.9%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$14.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.07x
long-term debt only, 2021-06-30 (60 months older than the period end); equity 2026-06-30
Cash flow to debt
-1.86x
TTM operating cash flow over long-term debt only, 2021-06-30 (60 months older than the period end)
Return on equity
+9.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+7.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+5.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$42.2M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2021-06-30 (60 months older than the period end), minus cash 2026-06-30
FCF yield
-31.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$813.5K$57.3K$3.8Kn/a
Gross profit$510.2K-$3.9M-$12.2Kn/a
Operating income-$46.7M-$48.7M-$25.4M-$26.9M
Net income-$45.3M-$49.8M-$27.3M-$28.0M
EPS (diluted)-9.40-59.81-53.15-0.83
Operating cash flow-$14.8M-$30.1M-$23.8M-$25.1M
Cash$6.3M$2.1M$14.8M$22.9M
SEC XBRL, fiscal years, as known on 2026-10-28

HYPD Stock Sonar score 6/7 axes

Find similar shapesCompare

HYPD ranks highest on growth (97th percentile) and profitability (87th), and lowest on risk and compliance (22nd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
87
Inputs
  • Return on equity+9.6% · 85 pct, sector of 545
  • Return on assets+7.9% · 88 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+5.8% · 88 pct, sector of 576
Financial health
51
Inputs
  • Debt to equity0.07x · 58 pct, sector of 352
  • Cash flow to debt-1.86x · 45 pct, sector of 371
Growth
97
Inputs
  • Revenue growth, YoY+1319% · 97 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
63
Inputs
  • Net Form 4 buying (codes P and S), 180d$30K · 69 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
30
Inputs
  • Funds adding, latest quarter19 · 30 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
22
Inputs
  • Short interest, % of float+9.4% · 41 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+74.5% · 2 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

HYPD filings, in plain words

Are Hyperion Defi insiders buying or selling HYPD?

In the 180 days to 2026-10-28, Hyperion Defi insiders were net buyers, a net $29.6K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Hyperion Defi insiders were net buyers of HYPD, a net $29.6K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies